Eric Winer

Eric Winer is Director of the Yale Cancer Center and one of the most influential clinical leaders in breast oncology. Over a distinguished career spanning Dana-Farber Cancer Institute and now Yale, he has shaped breast cancer clinical research through his scientific contributions and his leadership of the Alliance for Clinical Trials in Oncology and other national cooperative groups. His research interests have particularly centered on triple-negative breast cancer, a historically difficult-to-treat subtype, and on integrating immunotherapy into breast cancer regimens. Winer has contributed to pivotal studies evaluating immune checkpoint inhibitors in TNBC, including pembrolizumab and atezolizumab combinations with chemotherapy, which have led to FDA approvals in PD-L1-positive TNBC. He has also championed the study of olaparib and other PARP inhibitors in BRCA-mutated breast cancer, and has long been a voice for ensuring that clinical trials reflect the diversity of the patient population, particularly in terms of race and ethnicity. Beyond his scientific output, Winer has helped define quality measures in breast cancer care and has worked to improve care delivery in community settings. He is known as an exceptional mentor and has trained many of today's leading breast oncologists. His transition to lead Yale Cancer Center reflects the broad trust the oncology community places in his leadership and scientific vision.